Compare Stocks: CRIS, NRSN, NCEL, and KTTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.80 -3.7%	$5.84	$1.54 ▼ $39.00	$3.91M	3.13	266,000 shs	470,403 shs
KTTA Pasithea Therapeutics	$0.48 +0.5%	$0.50	$0.28 ▼ $2.06	$15.97M	0.29	317,107 shs	43,254 shs
NCEL NLS Pharmaceutics	$3.35 -6.9%	$3.59	$1.83 ▼ $28.03	$17.88M	0.94	10,422 shs	46,833 shs
NRSN NeuroSense Therapeutics	$0.45 +2.3%	$0.65	$0.39 ▼ $1.98	$16.73M	1.62	372,458 shs	55,308 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	-3.74%	-55.22%	-61.95%	-81.64%	-94.77%
KTTA Pasithea Therapeutics	+0.52%	-5.17%	+0.52%	-38.41%	-33.08%
NCEL NLS Pharmaceutics	-6.94%	+1.21%	-14.76%	+4.36%	-86.16%
NRSN NeuroSense Therapeutics	+2.26%	-9.36%	-36.97%	-45.19%	-63.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.80 -3.7%	$5.84	$1.54 ▼ $39.00	$3.91M	3.13	266,000 shs	470,403 shs
KTTA Pasithea Therapeutics	$0.48 +0.5%	$0.50	$0.28 ▼ $2.06	$15.97M	0.29	317,107 shs	43,254 shs
NCEL NLS Pharmaceutics	$3.35 -6.9%	$3.59	$1.83 ▼ $28.03	$17.88M	0.94	10,422 shs	46,833 shs
NRSN NeuroSense Therapeutics	$0.45 +2.3%	$0.65	$0.39 ▼ $1.98	$16.73M	1.62	372,458 shs	55,308 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	-3.74%	-55.22%	-61.95%	-81.64%	-94.77%
KTTA Pasithea Therapeutics	+0.52%	-5.17%	+0.52%	-38.41%	-33.08%
NCEL NLS Pharmaceutics	-6.94%	+1.21%	-14.76%	+4.36%	-86.16%
NRSN NeuroSense Therapeutics	+2.26%	-9.36%	-36.97%	-45.19%	-63.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRIS Curis	1.67	Reduce	$43.00	2,288.89% Upside
KTTA Pasithea Therapeutics	2.67	Moderate Buy	$3.00	524.35% Upside
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	586.57% Upside
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	1,775.97% Upside

Current Analyst Ratings Breakdown

Latest CRIS, NRSN, NCEL, and KTTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/24/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $43.00
7/17/2026	CRIS Curis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/29/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)
6/24/2026	KTTA Pasithea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	KTTA Pasithea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRIS Curis	$9.44M	0.40	N/A	N/A	$8.45 per share	0.21
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.39 per share	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRIS Curis	-$7.58M	-$23.80	N/A	N/A	N/A	-80.29%	N/A	-181.57%	N/A
KTTA Pasithea Therapeutics	-$20.43M	-$2.08	N/A	N/A	N/A	N/A	-57.44%	-53.61%	N/A
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)

Latest CRIS, NRSN, NCEL, and KTTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CRIS Curis	-$6.95	-$4.02	+$2.93	-$4.02	$1.00 million	N/A
8/14/2026	Q2 2026	KTTA Pasithea Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.30 million	N/A
5/15/2026	Q1 2026	KTTA Pasithea Therapeutics	-$0.45	-$0.12	+$0.33	-$0.12	$0.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRIS Curis	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRIS Curis	N/A	1.11	1.11
KTTA Pasithea Therapeutics	N/A	35.41	35.41
NCEL NLS Pharmaceutics	N/A	0.76	0.76
NRSN NeuroSense Therapeutics	N/A	0.31	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRIS Curis	29.97%
KTTA Pasithea Therapeutics	23.92%
NCEL NLS Pharmaceutics	N/A
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
CRIS Curis	5.78%
KTTA Pasithea Therapeutics	2.00%
NCEL NLS Pharmaceutics	16.40%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRIS Curis	60	2.09 million	1.97 million	No Data
KTTA Pasithea Therapeutics	3	33.41 million	32.75 million	Not Optionable
NCEL NLS Pharmaceutics	6	5.35 million	4.47 million	Not Optionable
NRSN NeuroSense Therapeutics	10	37.77 million	27.42 million	Not Optionable

CRIS, NRSN, NCEL, and KTTA Headlines

Recent News About These Companies

Neurosense Therapeutics (NRSN) Stock Forecast & Price Target

August 13 at 10:47 PM | investing.com

Neurosense Therapeutics Stock Price History

August 13 at 10:47 PM | investing.com

NeuroSense Issues CEO Letter to Shareholders

August 13 at 9:30 AM | prnewswire.com

Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) PT at $8.50

August 12 at 2:45 AM | americanbankingnews.com

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

August 6, 2026 | prnewswire.com

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split

July 31, 2026 | tipranks.com

NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective

July 31, 2026 | tipranks.com

Neurosense Therapeutics is a buy, this analyst says

July 28, 2026 | cantechletter.comC

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

July 22, 2026 | prnewswire.com

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

July 10, 2026 | theglobeandmail.com

NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

July 8, 2026 | nasdaq.com

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

July 6, 2026 | prnewswire.com

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

June 29, 2026 | prnewswire.com

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

June 25, 2026 | prnewswire.com

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

June 22, 2026 | prnewswire.com

NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 Shares

June 18, 2026 | insidertrades.com

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

June 11, 2026 | prnewswire.com

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

June 9, 2026 | prnewswire.com

NRSN Share News Today

May 19, 2026 | uk.investing.com

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

April 28, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, NRSN, NCEL, and KTTA Company Descriptions

Curis NASDAQ:CRIS

$1.80 -0.07 (-3.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.04 (+2.50%)

As of 08/14/2026 07:34 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Pasithea Therapeutics NASDAQ:KTTA

$0.48 +0.00 (+0.52%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.49 +0.01 (+2.81%)

As of 08/14/2026 07:55 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

NLS Pharmaceutics NASDAQ:NCEL

$3.35 -0.25 (-6.94%)

As of 08/14/2026 04:00 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NeuroSense Therapeutics NASDAQ:NRSN

$0.45 +0.01 (+2.26%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.64%)

As of 08/14/2026 07:21 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRIS, NRSN, NCEL, and KTTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRIS, NRSN, NCEL, and KTTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRIS, NRSN, NCEL, and KTTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, NRSN, NCEL, and KTTA Company Descriptions

Curis NASDAQ:CRIS

Pasithea Therapeutics NASDAQ:KTTA

NLS Pharmaceutics NASDAQ:NCEL

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRIS, NRSN, NCEL, and KTTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRIS, NRSN, NCEL, and KTTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRIS, NRSN, NCEL, and KTTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, NRSN, NCEL, and KTTA Company Descriptions

Curis NASDAQ:CRIS

Pasithea Therapeutics NASDAQ:KTTA

NLS Pharmaceutics NASDAQ:NCEL

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools